ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+39.51%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$340M
AUM Growth
+$340M
(-1.7%)
Cap. Flow
-$44M
Cap. Flow
% of AUM
-12.92%
Top 10 Holdings %
Top 10 Hldgs %
53.95%
Holding
62
New
15
Increased
11
Reduced
11
Closed
19
Top Buys
| 1 |
SAGE
Sage Therapeutics
SAGE
|
$13.8M |
| 2 |
CMPS
Compass Pathways
CMPS
|
$13.6M |
| 3 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$12.1M |
| 4 |
89bio
ETNB
|
$10.7M |
| 5 |
Celldex Therapeutics
CLDX
|
$8.08M |
Top Sells
| 1 |
Adverum Biotechnologies
ADVM
|
$36.5M |
| 2 |
BioXcel Therapeutics
BTAI
|
$18.1M |
| 3 |
ADAP
Adaptimmune Therapeutics
ADAP
|
$11.7M |
| 4 |
Iovance Biotherapeutics
IOVA
|
$9.05M |
| 5 |
Ascendis Pharma
ASND
|
$8.21M |
Sector Composition
| 1 | Healthcare | 79.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Arrowhead Research
ARWR
$3.05B
| $4.37M | 1.19% | 101,500 +41,500 | +69% | +$1.79M |
|
27
Cardiff Oncology
CRDF
$140M
| $4.34M | 1.18% | 305,900 -101,600 | -25% | -$1.44M |
|
28
Orchestra BioMed
OBIO
$147M
| $4.32M | 1.17% | +392,500 | New | +$4.32M |
|
|
AVDL
29
Avadel Pharmaceuticals
AVDL
$1.43B
| $3.55M | 0.97% | 705,218 -1,047,000 | -60% | -$5.28M |
|
30
Syndax Pharmaceuticals
SNDX
$1.41B
| $3.55M | 0.96% | 240,744 | – | – |
|
|
PANA.U
31
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
| $3.36M | 0.91% | +280,000 | New | +$3.36M |
|
32
Annexon
ANNX
$226M
| $3.33M | 0.9% | +110,000 | New | +$3.33M |
|
33
Xenon Pharmaceuticals
XENE
$2.98B
| $3.32M | 0.9% | 300,000 -217,500 | -42% | -$2.41M |
|
34
Fulcrum Therapeutics
FULC
$351M
| $3.03M | 0.82% | +381,500 | New | +$3.03M |
|
|
CNCE
35
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $2.95M | 0.8% | +300,000 | New | +$2.95M |
|
36
Verastem
VSTM
$569M
| $2.9M | 0.79% | 2,400,000 -250,000 | -9% | -$303K |
|
37
BioCryst Pharmaceuticals
BCRX
$1.74B
| $2.27M | 0.62% | 660,000 -1,240,000 | -65% | -$4.26M |
|
38
Axsome Therapeutics
AXSM
$6.05B
| $1.6M | 0.44% | 22,500 -67,500 | -75% | -$4.81M |
|
|
KRTX
39
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $1.04M | 0.28% | 13,500 -64,500 | -83% | -$4.99M |
|
40
Cogent Biosciences
COGT
$1.69B
| $959K | 0.26% | +410,000 | New | +$959K |
|
41
Clearside Biomedical
CLSD
$28.9M
| $947K | 0.26% | +615,000 | New | +$947K |
|
42
Wave Life Sciences
WVE
$1.53B
| $913K | 0.25% | 107,500 | – | – |
|
|
ADAP
43
Adaptimmune Therapeutics
ADAP
$15.6M
| – | – | -1,165,000 | Closed | -$11.7M |
|
|
44
Adverum Biotechnologies
ADVM
$64.6M
| – | – | -1,746,500 | Closed | -$36.5M |
|
|
AGEN
45
Agenus
AGEN
$133M
| – | – | -932,500 | Closed | -$3.67M |
|
46
Applied Therapeutics
APLT
$71M
| – | – | -182,000 | Closed | -$6.58M |
|
47
Arvinas
ARVN
$568M
| – | – | -123,000 | Closed | -$4.13M |
|
|
48
Ascendis Pharma
ASND
$11.8B
| – | – | -55,500 | Closed | -$8.21M |
|
|
49
BioXcel Therapeutics
BTAI
$59M
| – | – | -340,500 | Closed | -$18.1M |
|
50
Generation Bio
GBIO
$40.4M
| – | – | -100,000 | Closed | -$2.1M |
|